NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Bicara Therapeutics Inc. (BCAX) Stock Analysis

Bicara Therapeutics Inc. (BCAX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BCAX

$17.91

−$0.44 (−2.40%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BCAX with… →

BCAX Key Statistics

As of Oct 21, 2026
Trading
Open
$18.31
Previous Close
$18.35
Day's Range
17.90–18.78
52-Week Range
13.70–30.99
Volume
656.72K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.69
Valuation
Market Cap
$1.21B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.08
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$137.95M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
66.17M
1-Year Return
+4.98%
Dividend and dates
Earnings Date
November 10, 2026
Avg Volume
674.14K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BCAX closed at $17.91, +4.98% over 1 year.

Bicara Therapeutics Inc. (BCAX) has a market capitalization of $1.21B.

In fiscal 2025, BCAX reported revenue of $0.00.

BCAX Stock Return by Calendar Year

Bicara Therapeutics Inc. (BCAX) return since Sep 2024: what $10,000 became

1 year
$10,000 $10,498
+4.98%
Since Sep 2024
$10,000 $7,651
−23.49%

If you had invested $10,000 in Bicara Therapeutics Inc. (BCAX) at the close on September 13, 2024, the earliest close on record here, it would have been worth $7,651 at the close on October 21, 2026: −23.49% in total, −11.96% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+6.42%
2025−3.39%
2024 (partial year)−25.59%

As of October 21, 2026.

BCAX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$137.95M—
2024$0.00−$68.00M—
2023$0.00−$51.99M—
2022$0.00−$37.85M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$155.60M−$137.95M—
2024$0.00—−$82.39M−$68.00M—
2023$0.00—−$39.89M−$51.99M—
2022$0.00—−$37.66M−$37.85M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Bicara Therapeutics Inc. (BCAX) is capitalised at $1.21B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 103 employees.

BCAX last closed at $17.91 on October 21, 2026. That is −$0.44 (−2.40%) against the previous close. The 52-week range on file runs from $13.70 to $30.99. The latest close sits 30.73% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $137.95M. Trailing earnings per share are −3.08.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at −0.69. Daily returns over the trailing 2 years annualize to a volatility of 73.61%. Over the trailing twelve months the total return is +4.98%. The stored price history starts on September 13, 2024, and the total return since then is −23.49%.

Growth & Income

No dividend is on file for BCAX.

2026 is still running; the total return is +6.42% year to date. The record holds one complete calendar year, 2025, which returned −3.39%.

Peer Comparison

Bicara Therapeutics Inc. (BCAX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bicara Therapeutics Inc. BCAX $1.21B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Bicara Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Bicara Therapeutics Inc.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Visit website →